FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178406302> ?p ?o ?g. }

• W3178406302 endingPage "41" @default.
• W3178406302 startingPage "31" @default.
• W3178406302 abstract "Cytotoxicity is the main human killer cell property. The cytotoxicity reaction of human killer cells is achieved through a complex of molecules, including perforins, granzyme, cathepsin and others. However, only one molecule is enough for target cell death: granzyme. Other molecules are intended for granzyme activation and its delivery to the target cell cytoplasm. Granzymes are a whole family of serine proteases that perform their function in the human body as integral cytolytic effectors during programmed cell death of cancer and pathogen-infected cells. Secreted mainly by cytotoxic T-lymphocytes and NK-cells, granzymes initiate apoptosis via caspase-dependent and caspase-independent pathways. These natural properties make granzymes one of the most promising human enzymes for use in the development of targeted therapeutic strategies in the treatment of various types of cancer.The most promising is granzyme B, because it has the most powerful effector properties. Due to the initiation of cascade reactions that activate apoptosis, granzyme is attractive as a basis for the development of medicines applicable in clinical oncology. At this time, several approaches have been developed for delivering granzyme molecules to tumor cells and facilitating its penetration through the cell membrane. Moreover, some solutions are proposed to overcome the resistance of target cells to granzyme-mediated apoptosis. These approaches are discussed in this review.The purpose of this review was to systematize information on the use of granzyme B as a nanostructured drug delivery system in the treatment of solid and hematological malignancies. In addition, this review discusses ways to overcome the resistance of granzyme penetration into target cells." @default.
• W3178406302 created "2021-07-19" @default.
• W3178406302 creator A5057252478 @default.
• W3178406302 creator A5079460072 @default.
• W3178406302 creator A5088924152 @default.
• W3178406302 date "2021-07-14" @default.
• W3178406302 modified "2023-10-01" @default.
• W3178406302 title "NOVEL IMMUNOTHERAPEUTIC TARGETED GRANZYME DELIVERY SYSTEMS IN TREATMENT OF MALIGNANT TUMORS" @default.
• W3178406302 cites W110553717 @default.
• W3178406302 cites W1244359605 @default.
• W3178406302 cites W1558488007 @default.
• W3178406302 cites W1762255128 @default.
• W3178406302 cites W1939496502 @default.
• W3178406302 cites W1969336394 @default.
• W3178406302 cites W1970563206 @default.
• W3178406302 cites W1998056948 @default.
• W3178406302 cites W2012110635 @default.
• W3178406302 cites W2041673031 @default.
• W3178406302 cites W2051893458 @default.
• W3178406302 cites W2064881016 @default.
• W3178406302 cites W2066236445 @default.
• W3178406302 cites W2074731906 @default.
• W3178406302 cites W2076609293 @default.
• W3178406302 cites W2079613174 @default.
• W3178406302 cites W2084542841 @default.
• W3178406302 cites W2126120068 @default.
• W3178406302 cites W2128680377 @default.
• W3178406302 cites W2149443113 @default.
• W3178406302 cites W2150339137 @default.
• W3178406302 cites W2163602387 @default.
• W3178406302 cites W2166219468 @default.
• W3178406302 cites W2283489048 @default.
• W3178406302 cites W2291230569 @default.
• W3178406302 cites W2315617795 @default.
• W3178406302 cites W2316285546 @default.
• W3178406302 cites W2488453775 @default.
• W3178406302 cites W2564053079 @default.
• W3178406302 cites W2791218690 @default.
• W3178406302 cites W2920713080 @default.
• W3178406302 cites W2950047221 @default.
• W3178406302 cites W2982459484 @default.
• W3178406302 cites W3000355493 @default.
• W3178406302 cites W3003860544 @default.
• W3178406302 cites W4236436187 @default.
• W3178406302 doi "https://doi.org/10.17650/1726-9784-2021-20-2-31-41" @default.
• W3178406302 hasPublicationYear "2021" @default.
• W3178406302 type Work @default.
• W3178406302 sameAs 3178406302 @default.
• W3178406302 citedByCount "0" @default.
• W3178406302 crossrefType "journal-article" @default.
• W3178406302 hasAuthorship W3178406302A5057252478 @default.
• W3178406302 hasAuthorship W3178406302A5079460072 @default.
• W3178406302 hasAuthorship W3178406302A5088924152 @default.
• W3178406302 hasBestOaLocation W31784063021 @default.
• W3178406302 hasConcept C109316439 @default.
• W3178406302 hasConcept C121608353 @default.
• W3178406302 hasConcept C154317977 @default.
• W3178406302 hasConcept C167672396 @default.
• W3178406302 hasConcept C183193105 @default.
• W3178406302 hasConcept C185592680 @default.
• W3178406302 hasConcept C190283241 @default.
• W3178406302 hasConcept C202751555 @default.
• W3178406302 hasConcept C203014093 @default.
• W3178406302 hasConcept C2776062744 @default.
• W3178406302 hasConcept C2776090121 @default.
• W3178406302 hasConcept C2779968557 @default.
• W3178406302 hasConcept C2780380082 @default.
• W3178406302 hasConcept C31573885 @default.
• W3178406302 hasConcept C502942594 @default.
• W3178406302 hasConcept C51785407 @default.
• W3178406302 hasConcept C54355233 @default.
• W3178406302 hasConcept C55493867 @default.
• W3178406302 hasConcept C86803240 @default.
• W3178406302 hasConcept C8891405 @default.
• W3178406302 hasConcept C95444343 @default.
• W3178406302 hasConcept C96232424 @default.
• W3178406302 hasConcept C98424977 @default.
• W3178406302 hasConceptScore W3178406302C109316439 @default.
• W3178406302 hasConceptScore W3178406302C121608353 @default.
• W3178406302 hasConceptScore W3178406302C154317977 @default.
• W3178406302 hasConceptScore W3178406302C167672396 @default.
• W3178406302 hasConceptScore W3178406302C183193105 @default.
• W3178406302 hasConceptScore W3178406302C185592680 @default.
• W3178406302 hasConceptScore W3178406302C190283241 @default.
• W3178406302 hasConceptScore W3178406302C202751555 @default.
• W3178406302 hasConceptScore W3178406302C203014093 @default.
• W3178406302 hasConceptScore W3178406302C2776062744 @default.
• W3178406302 hasConceptScore W3178406302C2776090121 @default.
• W3178406302 hasConceptScore W3178406302C2779968557 @default.
• W3178406302 hasConceptScore W3178406302C2780380082 @default.
• W3178406302 hasConceptScore W3178406302C31573885 @default.
• W3178406302 hasConceptScore W3178406302C502942594 @default.
• W3178406302 hasConceptScore W3178406302C51785407 @default.
• W3178406302 hasConceptScore W3178406302C54355233 @default.
• W3178406302 hasConceptScore W3178406302C55493867 @default.
• W3178406302 hasConceptScore W3178406302C86803240 @default.
• W3178406302 hasConceptScore W3178406302C8891405 @default.
• W3178406302 hasConceptScore W3178406302C95444343 @default.

• next